STOCK TITAN
  1. Home
  2. News
  3. BNGO

Bionano Genomics Inc - BNGO STOCK NEWS

Welcome to our dedicated news page for Bionano Genomics (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bionano Genomics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bionano Genomics's position in the market.

News
Bionano Announces Amendment to Debt Financing Arrangement to Extend Cash Runway
Rhea-AI Summary
Bionano Genomics, Inc. announces an amendment to reduce outstanding debt through convertible notes, providing immediate access to $30.0 million of near-term liquidity. The company aims to expand capital and reduce debt on its balance sheet, enhancing financial flexibility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
none
-
News
American College of Medical Genetics and Genomics Includes OGM in Latest Edition of Technical Laboratory Standards for Solid Tumor Analysis
Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) announces the inclusion of optical genome mapping (OGM) in the ACMG technical laboratory standards for solid tumor analysis. OGM's high-resolution detection of structural variants is highlighted, emphasizing its utility in genome-wide analysis for solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
none
-
News
Bionano to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) announced that its CEO will participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13-14, 2024. Interested parties can schedule a meeting with Bionano through their BTIG representative.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.6%
Tags
conferences
News
Bionano’s Symposium 2024 Featured Presentations from its Global User Community Highlighting OGM as a Powerful Alternative to Classical Cytogenetics and Strong Complement to NGS
Rhea-AI Summary
Bionano Genomics, Inc. concluded its 2024 Symposium, featuring 32 oral presentations and 69 scientific posters from 92 countries. The event showcased the potential of optical genome mapping (OGM) in research applications for hematologic malignancies, genetic diseases, and cell and gene therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none
-
News
Bionano Announces Publication of a Study that Applied OGM to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer
Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) announced a peer-reviewed publication in Cancers detailing the use of optical genome mapping (OGM) to discover structural variants (SVs) driving drug resistance and sensitivity in cancer. The study analyzed 26 leukemia samples, revealing drug sensitivities and resistances associated with genomic rearrangements. OGM detected all SVs observed using classical cytogenetic methods and additional variants. The findings suggest potential new treatment strategies for leukemia, with implications for drug development and personalized medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Bionano Announces Publication of Interim Readout from Second Phase of Clinical Trial Analyzing Optical Genome Mapping as Standard of Care (SOC) for Prenatal Testing
Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of the second interim report from an ongoing clinical trial designed to support establishing OGM as part of standard of care (SOC) in the diagnosis of genetic disease for prenatal subjects. The study demonstrated that OGM has high sensitivity, specificity, and overall accuracy, making it a promising alternative to classical cytogenetic methods in prenatal diagnosis. The results of the study show that OGM can provide results comparable to two or three separate standard of care tests with just a single assay, indicating its potential to streamline genetic analysis processes and provide rapid, cost-effective solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.06%
Tags
clinical trial
News
Bionano Announces Full Commercial Release of the Stratys™ System for High Throughput Optical Genome Mapping
Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) has announced the full commercial release of the Stratys™ system, a high throughput optical genome mapping (OGM) system. The Stratys instrument offers up to a four-fold increase in raw data generation rate compared to the Saphyr® instrument and can process up to 12 single access chips without the need to batch multiple samples on a consumable. The data analysis for the Stratys system is powered by Stratys™ Compute, developed in collaboration with NVIDIA. 10 users across Canada, the United States, Europe, and Saudi Arabia have adopted a total of 11 Stratys systems as part of an early access program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications
Rhea-AI Summary
Bionano Genomics, Inc. announced its 2024 Symposium featuring 33 oral presentations by 26 customers worldwide, highlighting the utility of optical genome mapping across research applications in cancer, cell and gene therapy, and genetic disease. The 4-day virtual event will also unveil a new product. The company aims to bring the OGM community together to share research progress and drive further advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
none
-
News
Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care (SOC) in Genetic Disease Testing
Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced a peer-reviewed publication detailing results from the second phase of a large multisite clinical study designed to support establishing optical genome mapping (OGM) as part of the standard of care (SOC) in diagnosis of genetic disease for postnatal patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.23%
Tags
clinical trial
News
Bionano Announces 2024 Symposium: Four Consecutive Days of OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications
Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announces its 2024 Symposium, a virtual event featuring OGM presentations by 27 customers worldwide. The event will showcase applications in cancer, cell and gene therapy, and constitutional genetic disease. Bionano will also unveil a new product to advance cytogenetics and structural variant analysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.52%
Tags
none
Stock BNGO logo
Bionano Genomics Inc

Nasdaq:BNGO

BNGO Rankings

#4727 Ranked by Market Cap
#5501 Ranked by Stock Gains
N/A Ranked by Dividends

BNGO Stock Data

52.38M
54.49M
0.5%
11.91%
9.64%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
US
San Diego

About BNGO

at bionano genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. our team is not afraid to venture into uncharted territory to look for answers. we welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data. saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. at bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality o